The current review will focus on the role of the PI3K/AKT/mTOR pathway in lung cancer aggressiveness and promising drugs/natural compounds targeting this signaling pathway that are undergoing clinical or preclinical trials. This evidence concerns the gene AKT1 and lung cancer.